Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

First patient enrolled in phase IIa clinical study of ARQ-252 as potential treatment for vitiligo

March 19, 2021

MatriSys licenses MSB-3163 for acne from UCSD

March 19, 2021

JCR discontinues development of JR-031EB for epidermolysis bullosa

March 10, 2021

POPLAR study of imsidolimab in palmoplantar pustulosis does not meet primary endpoint

March 9, 2021

Topline data from BRAVE-AA2 phase III study of baricitinib in severe alopecia areata

March 4, 2021

BiomX begins phase II study of BX-001 for acne

March 3, 2021

VYNE advances development of FMX-114 combination topical gel for AD

March 3, 2021

Fighting Staphylococcus with Staphylococcus

March 3, 2021

Kymera begins dosing in first-in-human study of KT-474 for atopic dermatitis or HS

March 2, 2021

Hoth advances site recruitment for first-in-human study of BioLexa for atopic dermatitis

March 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...